Aug 2026· Psychiatry Research· Vol 366, pp.
117433
· 0 citations· 48 references
Medicine
TL;DR
Specific cognitive impairments may reflect the underlying pathology of early schizophrenia, and individuals can be reliably stratified into distinct cognitive phenotypes, provide critical clinical insights that can directly inform targeted, stratified strategies in early psychosis from a cognitive perspective.
Abstract
First-episode schizophrenia (FES) presents with substantial heterogeneity in cognitive performance, yet this variability is frequently overlooked in studies investigating disease pathology and treatment. This study aimed to quantify cognitive heterogeneity across domains and individuals, and to identify distinct cognitive subtypes in FES. We assessed cognitive performance using the MATRICS Consensus Cognitive Battery (MCCB) and clinical symptoms with the Positive and Negative Syndrome Scale (PANSS) in 271 patients with FES and 133 healthy controls (HC). Domain-specific impairment was quantified using Hedges' g, whereas quantile-based analyses were performed to characterize distributional heterogeneity in overall cognitive performance. Gaussian mixture clustering was subsequently applied to identify latent subtypes within FES group. Compared with HC, patients with FES demonstrated significant impairments across all assessed cognitive measures. However, the magnitude of impairment varied across measures, with Attention/Vigilance as the domain with the greatest impairment. Quantile-based analyses demonstrated that the FES-HC difference was significantly greater at the lower than at the upper end of the cognitive distribution, indicating that cognitive impairment was not uniformly distributed across patients. Clustering analysis identified two cognitive subtypes: one subgroup with severe global cognitive deficits and another with relatively preserved cognitive functioning. Crucially, these subtypes also differed significantly in their clinical symptom profiles. In conclusion, specific cognitive impairments may reflect the underlying pathology of early schizophrenia, and individuals can be reliably stratified into distinct cognitive phenotypes. These findings provide critical clinical insights that can directly inform targeted, stratified strategies in early psychosis from a cognitive perspective.
Cognitive heterogeneity is a core feature of schizophrenia (SCZ), but it remains unclear whether this heterogeneity reflects graded deviation within a shared cognitive structure or alterations in that structure. In this study, latent cognitive structure was delineated in healthy controls (HC) and evaluated in SCZ using...
This study provides a data-driven characterization of cognitive heterogeneity in MDD, identifying two cognitive dimensions spanning from relative preservation to widespread impairment, and provides preliminary biological context for interpreting cognitive heterogeneity in MDD.
Yu-Shun Yan, Jia'ao Yu, Liang Zuo et al.· Psychiatry and Clinical Neur...· 0 citations
White matter (WM) alterations are well documented in individuals at clinical high-risk for psychosis (CHR-P) and with recent-onset psychosis (ROP), yet it remains unclear whether they reflect vulnerability, psychosis-related symptom severity, or general impairments shared with other disorders such as depression. To dis...
N. Penzel, K. Cho, J. Seitz-Holland et al.· Molecular Psychiatry· 0 citations
Abstract Background Cognitive impairment is a core symptom in people with schizophrenia and represents an important treatment target. The MATRICS process identified seven cognitive domains particularly relevant to CIAS and recommended pencil and paper neuropsychological assessments of these domains. However, computeriz...
F. Cormack, M. Spilka, C. Lemvigh et al.· International Journal of Neu...· 0 citations
Clinical insight was most consistently associated with symptom severity, with an increasingly robust association over time, highlighting the need to assess insight across the symptom spectrum, including when symptoms are mild and independently of antipsychotic dosage.
L. Stabell, Erik Johnsen, R. Kroken et al.· Schizophrenia Research: Cogn...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.